Monday, February 2, 2026
25.2 C
Bengaluru

Is Your Field Force Optimised to Make the Most of Market Growth in Metros?

Summary of Performance of Top 30 Metros in IPM – Dec’24

Overall Market Performance
• The top 30 metros in India contributed 34% to the total IPM (Indian Pharmaceutical Market) sales for MAT (Moving Annual Total) Dec’24.
• These cities grew at a rate of 8.5%, slightly higher than the overall IPM growth of 7.6%.
• The total market value of these 30 metros increased from ₹71,831 Cr (Dec’23) to ₹77,929 Cr (Dec’24), showing a ₹6,098 Cr increase.

Fastest-Growing Markets
• Top 5 fastest-growing metros:
1. Pune (15%)
2. Agra (14%)
3. Lucknow (13%)
4. Nashik (13%)
5. Delhi (12.5%)
• Among the six mega metros, Delhi grew the fastest at 12.5%, followed by Chennai (11.6%) and Hyderabad (10.5%).

Growth Trends & Insights
• 13 out of 30 metros grew faster than the IPM growth rate (7.6%), while 17 metros grew at or below the IPM growth rate.
• Cities like Delhi, Hyderabad, Bangalore, and Chennai remain dominant in total market value, with Delhi leading at ₹10,756 Cr.
• Smaller cities like Bhopal (12%) and Nashik (13%) showed strong growth, indicating increasing pharmaceutical demand in Tier-2 cities.

Conclusion

The Indian pharmaceutical market continues to grow robustly, especially in urban centers. While mega metros remain strong contributors, smaller cities like Lucknow, Pune, and Agra are emerging as high-growth markets. The steady expansion of IPM in these metros suggests increasing healthcare accessibility and demand for pharmaceutical products in urban India.

Hot this week

Quality, Not Price: Why the Generic Drug Debate Keeps Missing the Point

In an earlier article in The Wire Science, I...

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...

Indian Pharma Market in 2025: Decoding Growth, Therapy Shifts, and the Road Ahead

The latest PharmaTrac report for December 2025 offers a...

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry...

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

Topics

IQVIA vs. PharmaTrac: Indian Pharma Market Data

Here is an analytical blog comparing the IQVIA MFR...

Orphan Drugs and Indian Pharma: Moving from Volume to Value?

Zydus’ ZYCUBO May Be the Proof Point the Industry...

Arjun Arunachalam: The Man Who Deleted Helium

For more than fifty years, the MRI industry treated...

Who Is Monitoring Quality in India’s Small Drug Units?

The Telangana Drugs Control Administration’s stop-use notice on a...

Zydus vs. Helsinn — What It Really Means for Indian Pharma

On December 24, 2025, the Delhi High Court delivered...

Worldclass Healthcare But Out of Reach for Most Indians?

When an eminent cardiologist like Dr. Sunil Chandy—former Director...
spot_img

Related Articles

spot_imgspot_img